NDLI: Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Please wait, while we are loading the content...

Year: 2017 Volume: 39

Year: 2016 Volume: 38

Year: 2015 Volume: 37

Year: 2014 Volume: 36

Year: 2013 Volume: 35

Year: 2012 Volume: 34

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Angiotensin II receptor blockers in the treatment of the cardiovascular disease continuum.

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.

Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.

Long-term persistence with statin therapy: a nationwide register study in Finland.

Prescribing of beta-blockers after myocardial infarction: a preliminary study of physician motivations and barriers.

Year: 2007 Volume: 29

Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Motovska, Zuzana Kala, Petr
Description	Country affiliation: Czech Republic Author Affiliation: Motovska Z ( Third Medical Faculty, Charles University, and University Hospital Kralovske Vinohrady, 100 34 Prague 10, Czech Republic. zuzana.motovska@iex.cz)
Abstract	BACKGROUND: Aggressive antiplatelet treatment is currently an established practice in patients with coronary artery disease. OBJECTIVE: This article discusses the evidence from clinical trials and registries concerning the benefits and risks of clopidogrel in relation to the dose and timing of treatment and its use in particular patient populations (stratified by risk factors for major adverse cardiovascular events). METHODS: Human clinical trials, registries, and in vitro human platelet studies were identified through searches of MEDLINE, Scopus, Google Scholar, and ClinicalTrials.gov (January 1980-July 2008) using the terms clopidogrel in coronary artery disease, clopidogrel loading dose, clopidogrel pretreatment, and antiplatelet therapy for coronary artery disease. For inclusion in the review, publications had to compare clopidogrel administered at different doses and times across the spectrum of patients with coronary artery disease; present outcome data on mortality, reinfarction, stroke, or their combination; and report safety data pertaining to bleeding risk. RESULTS: The results of randomized trials support the benefit of administering a 300-mg loading dose of clopidogrel as part of both conservative and invasive strategies for the management of acute coronary syndromes (ACS). In a small randomized trial in patients with non-ST-segment elevation ACS, pretreatment with clopidogrel 600 mg >12 hours before coronary stenting was associated with significantly fewer major adverse cardiovascular events compared with pretreatment with clopidogrel 300 mg (P = 0.020). A randomized trial in patients with ACS undergoing percutaneous coronary intervention (PCI) reported a significant reduction in ischemic risk with prasugrel (60-mg loading dose, 10-mg/d maintenance dose) compared with clopidogrel (300-mg loading dose, 75-mg/d maintenance dose) (P < 0.001); however, the clinical benefit with prasugrel was accompanied by a significant increase in the risk of life-threatening bleeding (P = 0.01). Pretreatment with a 300-mg clopidogrel loading dose administered at least 15 hours before elective PCI was associated with a significant reduction in periprocedural ischemic events compared with 75 mg given after PCI (P = 0.028). In another randomized trial in patients undergoing elective PCI, pretreatment with clopidogrel 600 mg before diagnostic catheterization was associated with a significantly increased risk of minor bleeding complications (P = 0.027) without a significant benefit in terms of the primary ischemic end point. Data from registries support the use of a 300-mg loading dose of clopidogrel for the standard care of patients with ACS and indicate no significant benefit for pretreatment with loading doses >300 mg. One study of registry data found that pretreatment with clopidogrel 300 mg before elective PCI was associated with a significant reduction in major adverse cardiovascular events compared with a loading dose given immediately before or after the intervention (P = 0.002). CONCLUSIONS: Suppression of platelet activity through the use of antithrombotic agents should be balanced against the risk of atherothrombotic events. In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk. In patients undergoing elective PCI, pretreatment with clopidogrel 300 mg administered >15 hours before the procedure achieved the optimal risk-benefit ratio. In cases of unplanned PCI, administration of clopidogrel 600 mg immediately after diagnostic catheterization was well tolerated and effective.
File Format	HTM / HTML
ISSN	01492918
Volume Number	30 Pt 2
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2008-01-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Coronary Artery Disease Drug Therapy Platelet Aggregation Inhibitors Therapeutic Use Ticlopidine Analogs & Derivatives Acute Coronary Syndrome Angioplasty, Balloon, Coronary Dose-response Relationship, Drug Hemorrhage Chemically Induced Humans Platelet Activation Drug Effects Randomized Controlled Trials As Topic Registries Risk Assessment Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in